Matthew Bridgland‐Taylor
AstraZeneca (United Kingdom)(GB)
Publications by Year
Research Areas
Cardiac electrophysiology and arrhythmias, Ion channel regulation and function, Neuroscience and Neural Engineering, Cardiac Imaging and Diagnostics, Cardiac pacing and defibrillation studies
Most-Cited Works
- → A New Perspective in the Field of Cardiac Safety Testing through the Comprehensive In Vitro Proarrhythmia Assay Paradigm(2015)307 cited
- → Prediction of Thorough QT study results using action potential simulations based on ion channel screens(2014)96 cited
- → A Correlation Between the In Vitro Drug Toxicity of Drugs to Cell Lines That Express Human P450s and Their Propensity to Cause Liver Injury in Humans(2013)75 cited
- → Cross-site and cross-platform variability of automated patch clamp assessments of drug effects on human cardiac currents in recombinant cells(2020)59 cited
- → Evaluation of drug‐inducedQTinterval prolongation in animal and human studies: a literature review of concordance(2015)55 cited
- → A systematic strategy for estimating hERG block potency and its implications in a new cardiac safety paradigm(2020)45 cited
- → Validation of a voltage-sensitive dye (di-4-ANEPPS)-based method for assessing drug-induced delayed repolarisation in Beagle dog left ventricular midmyocardial myocytes(2009)25 cited
- → Prediction and Modeling of Effects on the QTc Interval for Clinical Safety Margin Assessment, Based on Single-Ascending-Dose Study Data with AZD3839(2014)14 cited
- → Mutations of the nACh Receptor M4 Helix Reveal Different Phenotypes in Different Expression Systems: Could Lipids be Responsible?(2022)4 cited
- → Validation of a cardiac L-type calcium channel assay using IonWorks™(2010)4 cited